Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States

被引：0
|
作者：
Zakharia, Yousef
Vlahiotis, Anna
Siu, Gordon
Rao, Dharanija
Teresi, Rosemary
Eccleston, Anthony
机构：
[1] Univ Iowa, Iowa City, IA USA
[2] Pfizer, New York, NY USA
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Inc, Mentor, OH USA
[5] Pfizer Inc, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16553
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States
    Moon, Helen H.
    Kearney, Mairead
    Mahmoudpour, Seyed Hamidreza
    Ike, Chiemeka
    Morris, Valerie
    Rava, Andrew
    Kim, Sonia
    Sun, Haiyan
    Boyd, Marley
    Gomez Rey, Gabriel
    CURRENT ONCOLOGY, 2024, 31 (09) : 5662 - 5676
  • [42] Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) in the United States
    Geynisman, D.
    Chan, P.
    Robert, N.
    Chen, L.
    Del Tejo, V.
    Rosenblatt, L. C.
    Huo, S.
    Doshi, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1216 - S1216
  • [43] Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
    Zheng, Huanrui
    Zhou, Jin
    Tong, Yao
    Zhang, Jinhua
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [44] REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS
    Cowey, C. L.
    Mahnke, L.
    Espirito, J.
    Helwig, C.
    Oksen, D.
    Bharmal, M.
    VALUE IN HEALTH, 2017, 20 (05) : A95 - A95
  • [45] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
    Kozak, Katarzyna
    Teterycz, Pawel
    Galus, Lukasz
    Mackiewicz, Jacek
    Galwas-Kliber, Katarzyna
    Kaminska-Winciorek, Grazyna
    Brandys, Piotr
    Cybulska-Stopa, Bozena
    Kempa-Kaminska, Natasza
    Zietek, Marcin
    Zubrowska, Justyna
    Dziura, Robert
    Dembinski, Mateusz
    Bereza, Michal
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma
    Ahn, Daniel
    Sidel, Michelle
    Panattoni, Laura
    Sacks, Naomi
    Hernandez, Jennifer
    Villacorta, Reginald
    FUTURE ONCOLOGY, 2022, 18 (30) : 3419 - 3433
  • [47] Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination
    Aydogdu, C.
    Paffenholz, P.
    Stelmach, R.
    Schlack, K.
    Roghmann, F.
    Handke, A.
    Mandal, S.
    Schnabel, M.
    Merseburger, A.
    Ivanyi, P.
    Tschaebitz, S.
    Darr, C.
    Gruenwald, V.
    Stief, C. G.
    Casuscelli, J.
    EUROPEAN UROLOGY, 2024, 85 : S1858 - S1858
  • [48] Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.
    De Vries, Manon
    Hamilou, Zineb
    Ghosh, Sunita
    Heng, Daniel Yick Chin
    Wood, Lori
    Basappa, Naveen S.
    Kollmannsberger, Christian K.
    Graham, Jeffrey
    Bhindi, Bimal
    Finelli, Antonio
    Bjarnason, Georg A.
    Bosse, Dominick
    Pouliot, Frederic
    Castonguay, Vincent
    Breau, Rodney H.
    Saleh, Ramy R.
    Winquist, Eric
    Lalani, Aly-Khan A.
    Soulieres, Denis
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [49] COST-EFFECTIVENESS OF PEMBROLIZUMAB plus AXITINIB VERSUS NIVOLUMAB plus IPILIMUMAB AS FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL
    Garmatter, L. P. Leonart
    Berlinski, F.
    Rego, M. A. D. C.
    Bastos, D. A.
    Soares, A.
    Kater, F. R.
    Nunes, A. A.
    Santos, M.
    Riveros, B. Salgado
    VALUE IN HEALTH, 2023, 26 (06) : S149 - S150
  • [50] Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.
    Allison, Jennifer
    Charnley, Natalie
    Stevenson, Robert
    Waddell, Tom
    Pillai, Manon Rhys
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345